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ABSTRACT
Background: While procarbazine, CCNU (lomustine), and vincristine (PCV) has been an 
alternative chemotherapy option for malignant gliomas, it is worth investigating whether 
the combination of only procarbazine and CCNU is comparable because vincristine adds 
toxicity with uncertain benefit. The purpose of this study was to evaluate the feasibility of 
procarbazine and CCNU chemotherapy for recurrent glioblastoma multiforme (GBM) with 
O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation.
Methods: Eight patients with recurrent GBM following concurrent chemoradiotherapy and 
temozolomide (TMZ) adjuvant therapy were enrolled in this trial; they received no other 
chemotherapeutic agents or target therapy. They received CCNU (75 mg/m2) on day 1 and 
procarbazine (60 mg/m2) through days 11 and 24 every 4 weeks. The median cycle of CCNU 
and procarbazine was 3.5 (range: 2–6).
Results: One patient achieved stable disease. The median progression-free survival (PFS) 
with procarbazine and CCNU chemotherapy was eight weeks (range: 5–73), and the PFS rates 
were 25% and 12.5% at 16 and 30 weeks, respectively. The median overall survival (OS) from 
the initial diagnosis to death was 40 months, and the median OS from the administration of 
procarbazine and CCNU chemotherapy to death was 9.7 months (95% confidence interval: 
6.7–12.7). Serious adverse events were found at six visits, and two cases were considered to be 
grade 3 toxicities.
Conclusion: The efficacy of procarbazine and CCNU chemotherapy is not satisfactory. 
This study suggests the need to develop other treatment strategies for recurrent and TMZ-
refractory GBM. Trial registry at ClinicalTrials.gov, NCT017337346.
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INTRODUCTION
The prognosis for glioblastoma multiforme (GBM) patients remains poor despite advances 
in surgical techniques, radiotherapy, and chemotherapy. The median overall survival (OS) 
is expected to be only 14.6 months after maximum safe resection and irradiation with 
concurrent and adjuvant temozolomide (TMZ) chemotherapy. In spite of multimodal 
therapies, most patients suffer recurrence and die within 40 weeks,1,2 and there is no 
consensus on treating recurrent and TMZ-refractory GBM. Bevacizumab, a humanized 
monoclonal antibody against vascular endothelial growth factor A, has shown significant 
biological activity in patients with recurrent GBM and has been under investigation with 
other target agents.3 Re-challenge with alternative-dose TMZ for recurrent GBM can be 
recommended even if the patient has a history of standard TMZ chemotherapy.4,5
Nitrosourea has become a second choice after TMZ for malignant gliomas.6 Retrospective 
and subgroup analyses suggest higher efficacy for procarbazine, CCNU (lomustine), and 
vincristine (PCV) chemotherapy than for TMZ in patients with anaplastic glioma, with 
good prognosis as well.7,8 With the PCV triple-drug regimen, CCNU (110 mg/m2, day 1) and 
procarbazine (60 mg/m2, days 8–21) are administered orally but vincristine is administered 
intravenously (maximum 2 mg, days 8 and 29). The molecular weight of vincristine is 825 
daltons, so that it has less permeability through the blood-brain barrier.9 It is well-known 
that vincristine is associated with neurotoxicity and could impair the quality of life in brain 
cancer patients, and the number of outpatient visits will decrease by omitting intravenous 
administration of vincristine. Authors of one study reported that reducing CCNU dose by 
30% reduced the hematological toxicity (grade 3/4) from 25.6% to 13%.10 Based on these 
findings, we designed a modified procarbazine and CCNU therapy protocol for treating 
recurrent GBM with O6-methylguanine-DNA-methyltransferase (MGMT) promoter 
methylation. The purpose of this study was to evaluate the feasibility of the procarbazine and 
CCNU chemotherapy for recurrent GBM with MGMT promoter methylation.
METHODS
Study population
We enrolled patients at least 20 years of age who had been diagnosed with pathologically 
confirmed GBM with MGMT promoter methylation, which we assessed by methylation-
specific polymerase chain reaction (PCR); we allocated patients with recurrent GBM with 
an unmethylated MGMT promoter to another trial. Radiographically confirmed tumor 
progression by magnetic resonance imaging (MRI) following standard external beam 
fractionated radiotherapy and TMZ chemotherapy was required for enrollment, along with 
a minimum Karnofsky performance status of 60, adequate hematologic, hepatic, and renal 
function, and at least a two-week period from any prior surgery or other chemotherapy. The 
following patient groups were excluded: 1) those with other cancer history, 2) those who had 
been treated with CCNU or procarbazine, and 3) those with leptomeningeal seeding.
Treatment schedule
The patients had previously been treated with concurrent chemoradiotherapy (CCRT) with 
adjuvant TMZ following the initial diagnosis of GBM. We determined recurrence by MRI scans 
assessed using the Response Assessment in Neuro-Oncology criteria. CCNU (75 mg/m2) was 
administered on day 1 and procarbazine (60 mg/m2) was administered through days 11 and 
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24 every 4 weeks. Administration of CCNU and procarbazine was repeated every 28 days for 
up to 6 months. We evaluated all toxicities according to the Common Terminology Criteria 
for Adverse Events version 4.0. All patients underwent brain MRI at the baseline within two 
weeks of starting CCNU, and they were evaluated by laboratory examinations of blood and 
neurological evaluation every four weeks; they also underwent gadolinium-enhanced brain 
MRI after every two cycles of chemotherapy (i.e., every eight weeks). Specifically, we required 
stable or decreasing corticosteroid dose and stable or improved fluid-attenuated inversion 
recovery abnormality for a rating of complete response, partial response, or stable disease 
based on complete, partial, or no decrease in the enhancing tumor burden on standard post-
gadolinium T1-weighted sequences.
Study design and statistical analysis
We calculated the sample size using the following formula:
where n is the required sample size, p is the known response rate, 0.15, q is 0.85 (1−p), α is 
0.05, and d is the drop rate, 0.05. Approximately 52 patients needed to be enrolled for the 
study to achieve a difference from the historical control.
Progression-free survival (PFS) was the primary end point of this study. Secondary end points 
were OS using Kaplan-Meier estimation and safety of combining CCNU and procarbazine in 
patients with recurrent GBM.
We estimated PFS from the start of CCNU and procarbazine administration to tumor 
progression or dropout from the study and OS from the start of CCNU and procarbazine 
administration to the date of death, irrespective of its cause. We assessed PFS and OS by the 
Kaplan-Meier product-limit method for all patients using SPSS software version 18.0 (IBM 
Corp., Chicago, IL, USA).
Ethics statement
The prospective, multicenter clinical trial was approved by the Institutional Review Board of 
Korean Ministry of Food and Drug Safety (No. 12096) and recorded with ClinicalTrials.gov 
Identifier NCT017337346.
RESULTS
The patients were four males and four females with a median age of 56.5 years (range: 23–67), 
and their median Karnofsky performance scale at enrollment was 80% (range: 60–100). All 
patients had previously been treated with CCRT and adjuvant TMZ chemotherapy but no 
other chemotherapy or targeted agents. The median time between the initial GBM diagnosis 
and enrollment in the study was 8.75 months (range: 5.5–57).
The median cycle of CCNU and procarbazine was 3.5 (range: 2–6). Seven patients and 
one patient, respectively, achieved disease progression and stable disease following the 
administration of CCNU and procarbazine (Table 1).
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The median PFS for CCNU and procarbazine therapy to treat recurrent GBM was eight 
weeks (range: 5–73). PFS rates were 25% and 12.5% at 16 and 30 weeks, respectively, and the 
median OS from the start of CCNU and procarbazine administration to death was 9.7 months 
(95% confidence interval: 6.7–12.7, Fig. 1). The median OS from the initial diagnosis was 
40 months. Serious adverse events are summarized in Table 2. Grade 3 toxicities including 
elevated hepatic enzyme and leukopenia developed in two patients, but they recovered 
following the delay of CCNU and procarbazine administration. In one patient, generalized 
muscle weakness developed and recovered without delay of the chemotherapy schedule. One 
patient had disseminated intravenous coagulation three times during follow-up period and 
was given conservative care.
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Table 1. Patient characteristics
No. Age Sex Initial site Surgery CCRT Adjuvant 
TMZ, cycle
KPS at 
recurrence
CCNU and 
procarbazine, cycle
Response F/U, mon Status
1 67 M Corpus callosum Biopsy Y 3 100 3 PD 35.3 Alive
2 52 F Thalamus Biopsy Y 6 60 6 SD 36.7 Alive
3 60 M Frontal Craniotomy Y 6 60 2 PD 64.0 Dead
4 23 F Parietal Craniotomy Y 5 90 6 PD 18.7 Dead
5 60 F Corpus callosum Biopsy Y 4 70 3 PD 13.0 Dead
6 50 F Temporal Craniotomy Y 2 100 2 PD 12.3 Alive
7 31 M Frontal Craniotomy Y 1 80 4 PD 9.0 Dead
8 66 M Parietal Craniotomy Y 5 70 4 PD 12.5 Dead
CCRT = concurrent chemoradiotherapy, TMZ = temozolomide, KPS = Karnofsky performance scale, F/U = follow-up, PD = progression of disease, SD = stable 
disease.
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Fig. 1. Kaplan-Meier analysis. (A) Progression-free survival. (B) Overall survival.
Table 2. Serious adverse events
Adverse events All Grade
1 2 3 4
Increased alanine aminotransferase 1 - - 1 -
Leukopenia 1 - - 1 -
Disseminated intravenous coagulation 3 - 3 - -
Generalized muscle weakness 1 - 1 - -
Total 6 - 4 2 -
DISCUSSION
In this study, the median PFS was two months in recurrent and TMZ-refractory GBM patients 
treated with modified CCNU and procarbazine chemotherapy; all patients had received 
radiotherapy with concomitant TMZ and cyclic TMZ therapy but no other cytotoxic agents or 
target therapies. CCNU is increasingly considered an alternative chemotherapeutic agent for 
GBM treatment because no other treatment has yielded better results in a controlled clinical 
trial, but PFS rates at six months are only in the range of 15%–25% with CCNU therapy.11,12 
The first randomized trial of PCV versus TMZ in chemotherapy-naïve patients with recurrent 
malignant glioma found that median PFS was 3.6 months with PCV and 4.7 months with 
TMZ (P = 0.229). In one study,13 the proportions of patients with at least one grade 3/4 
adverse event were 9.2% and 12.2% in the PCV and TMZ arms (P = 0.40), respectively, and in 
a single-institution analysis, grade 3/4 hematological toxicity occurred in 25.6% of patients 
with recurrent GBM during traditional PCV chemotherapy.10
The characteristics of our protocol were that we omitted vincristine administration and we 
reduced the CCNU dose to increase the treatment's tolerability. Vincristine adds toxicity and 
CNS penetration is suboptimal,14-16 and a retrospective analysis of CCNU and procarbazine 
versus PCV for grades 2 and 3 oligodendrogliomas presented no differences in PFS or 
OS.17,18 A greater proportion of patients experienced neutropenia with PCV, but only those 
who received vincristine experienced neurotoxicity (14% vs. 0%). The NOA-05 multicenter 
trial analyzed the efficacy of traditional CCNU and procarbazine chemotherapy in patients 
with gliomatosis cerebri, and these patients achieved median PFS of 14 months. During 
124 cycles of chemotherapy, authors observed grade 3/4 hematological toxicity in 15% of 
patients.19
There are no clinical publications that address whether CCNU and procarbazine can be 
substituted for PCV for newly diagnosed or recurrent GBM. We here attempted to assess the 
feasibility of modified CCNU and procarbazine chemotherapy for recurrent, TMZ-refractory 
GBM. We searched for clinical articles using the keywords “recurrent,” “glioblastoma,” 
“chemotherapy,” and “Korea” in PubMed (Table 3).20-23 We excluded articles about 
radiation therapy or radiosurgery. TMZ and the combination of ACNU and cisplatin were 
analyzed in three reports and one report, respectively. ACNU and cisplatin regimen had 
myelosuppression issues.20 Two reports analyzed the efficacy of continuous low-dose TMZ 
administration for recurrent and TMZ-refractory GBM. They showed different outcomes 
in terms of PFS and OS.22,23 In the phase II RESCUE study (continuous TMZ 50 mg/m2/d), 
six-month PFS was 23.9% in patients with recurrent GBM.24 The efficacy of modified CCNU 
and procarbazine chemotherapy could be comparable with that of continuous low-dose TMZ 
therapy as a salvage therapy for recurrent GBM.
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Table 3. Summary of clinical trials for recurrent glioblastoma treated with chemotherapeutic agents in Korea
Year No. of 
patients
Type of study No. of 
institution
Chemotherapy  
regimen
Median progression 
free survival
Median overall 
survival
Adverse effects
2005 37 Retrospective 1 ACNU, cisplatin 6 mon 9 mon Grade 3/4 leukopenia: 41%
2006 16 Retrospective 1 Temozolomide  
(5 days every 28 days)
8 wk 17 wk Grade 3/4 leukopenia: 0%
2010 38 Retrospective 1 Temozolomide (daily) 17 wk 41 wk Grade 3 lymphopenia: 3 patients
2015 30 Retrospective 1 Temozolomide (daily) 8 wk 6 mon Grade 3/4 leukopenia: 0%
The present study 8 Prospective 6 Procarbazine, CCNU 8 wk 9.7 mon Grade 3 leukopenia: 1 patient
It cannot yet be determined whether the dose reduction decreased hematological toxicities 
because of the small number of patients and the short follow-up. Although PCV increased 
survival among selected patients, its toxic effects led to many dose delays and reductions 
during the course of treatment, whereas during a total of 30 cycles of modified CCNU and 
procarbazine chemotherapy, only one cycle was delayed due to leukopenia.
This is the first prospective, multicenter clinical trial for GBM approved by the Korean Food 
Institute Institutional Review Board. The limitation of the study is the small number of 
patients. Following the statistic calculation, 52 patients needed to be enrolled to achieve a 
difference from the historical control; however, this trial terminated before the expected 
end date because of the progressive deterioration of patients with recurrent GBM and slow 
candidate enrollment. These experiences and information should encourage clinicians and 
clinical researchers to suggest more challenging clinical trials in the future.
In conclusion, our findings show marginal efficacy of modified CCNU and procarbazine 
chemotherapy. This clinical trial suggests the need to develop treatment strategies beyond 
CCNU and procarbazine for recurrent, TMZ-refractory GBM.
ACKNOWLEDGMENTS
Three neuropathologists (Drs. Kim SH, Park SH, and Lee YS) independently conducted the 
pathology reviews.
REFERENCES
 1. Kyritsis AP, Levin VA. An algorithm for chemotherapy treatment of recurrent glioma patients after 
temozolomide failure in the general oncology setting. Cancer Chemother Pharmacol 2011;67(5):971-83. 
PUBMED | CROSSREF
 2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus 
concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-96. 
PUBMED | CROSSREF
 3. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab 
followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 
2009;27(5):740-5. 
PUBMED | CROSSREF
 4. Franceschi E, Omuro AM, Lassman AB, Demopoulos A, Nolan C, Abrey LE. Salvage temozolomide for 
prior temozolomide responders. Cancer 2005;104(11):2473-6. 
PUBMED | CROSSREF
 5. Wick W, Platten M, Weller M. New (alternative) temozolomide regimens for the treatment of glioma. 
Neuro Oncol 2009;11(1):69-79. 
PUBMED | CROSSREF
 6. Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, et al. European 
Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and 
oligodendroglial gliomas. Lancet Oncol 2017;18(6):e315-29. 
PUBMED | CROSSREF
 7. Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, et al. International retrospective 
study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol 2011;13(6):649-59. 
PUBMED | CROSSREF
 8. Wick W, Roth P, Hartmann C, Hau P, Nakamura M, Stockhammer F, et al. Long-term analysis of the 
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or 
temozolomide. Neuro Oncol 2016;18(11):1529-37.
PUBMED
6/7https://jkms.org https://doi.org/10.3346/jkms.2018.33.e167
Procarbazine and CCNU for Recurrent Glioblastoma
 9. Wang F, Zhou F, Kruh GD, Gallo JM. Influence of blood-brain barrier efflux pumps on the distribution of 
vincristine in brain and brain tumors. Neuro Oncol 2010;12(10):1043-9. 
PUBMED | CROSSREF
 10. Yang SH, Hong YK, Yoon SC, Kim BS, Lee YS, Lee TK, et al. Radiotherapy plus concurrent and adjuvant 
procarbazine, lomustine, and vincristine chemotherapy for patients with malignant glioma. Oncol Rep 
2007;17(6):1359-64.
PUBMED
 11. Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, et al. Phase III randomized 
trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus 
lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 2013;31(26):3212-8. 
PUBMED | CROSSREF
 12. Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma--are 
we there yet? Neuro Oncol 2013;15(1):4-27. 
PUBMED | CROSSREF
 13. Brada M, Stenning S, Gabe R, Thompson LC, Levy D, Rampling R, et al. Temozolomide versus 
procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol 2010;28(30):4601-8. 
PUBMED | CROSSREF
 14. Boyle FM, Eller SL, Grossman SA. Penetration of intra-arterially administered vincristine in experimental 
brain tumor. Neuro Oncol 2004;6(4):300-5. 
PUBMED | CROSSREF
 15. Greig NH, Soncrant TT, Shetty HU, Momma S, Smith QR, Rapoport SI. Brain uptake and anticancer 
activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and 
binding to plasma constituents in rat. Cancer Chemother Pharmacol 1990;26(4):263-8. 
PUBMED | CROSSREF
 16. Levin VA. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary 
permeability. J Med Chem 1980;23(6):682-4. 
PUBMED | CROSSREF
 17. Vesper J, Graf E, Wille C, Tilgner J, Trippel M, Nikkhah G, et al. Retrospective analysis of treatment 
outcome in 315 patients with oligodendroglial brain tumors. BMC Neurol 2009;9(1):33. 
PUBMED | CROSSREF
 18. Webre C, Shonka N, Smith L, Liu D, De Groot J. PC or PCV, that is the question: primary anaplastic 
oligodendroglial tumors treated with procarbazine and CCNU with and without vincristine. Anticancer Res 
2015;35(10):5467-72.
PUBMED
 19. Glas M, Bähr O, Felsberg J, Rasch K, Wiewrodt D, Schabet M, et al. NOA-05 phase 2 trial of procarbazine 
and lomustine therapy in gliomatosis cerebri. Ann Neurol 2011;70(3):445-53. 
PUBMED | CROSSREF
 20. Gwak HS, Youn SM, Kwon AH, Lee SH, Kim JH, Rhee CH. ACNU-cisplatin continuous infusion 
chemotherapy as salvage therapy for recurrent glioblastomas: phase II study. J Neurooncol 2005;75(2):173-80. 
PUBMED | CROSSREF
 21. Yang SH, Kim MK, Lee TK, Lee KS, Jeun SS, Park CK, et al. Temozolomide chemotherapy in patients with 
recurrent malignant gliomas. J Korean Med Sci 2006;21(4):739-44. 
PUBMED | CROSSREF
 22. Kong DS, Lee JI, Kim JH, Kim ST, Kim WS, Suh YL, et al. Phase II trial of low-dose continuous 
(metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol 2010;12(3):289-96. 
PUBMED | CROSSREF
 23. Woo JY, Yang SH, Lee YS, Lee SY, Kim J, Hong YK. Continuous low-dose temozolomide chemotherapy 
and microvessel density in recurrent glioblastoma. J Korean Neurosurg Soc 2015;58(5):426-31. 
PUBMED | CROSSREF
 24. Perry JR, Bélanger K, Mason WP, Fulton D, Kavan P, Easaw J, et al. Phase II trial of continuous dose-
intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 2010;28(12):2051-7. 
PUBMED | CROSSREF
7/7https://jkms.org https://doi.org/10.3346/jkms.2018.33.e167
Procarbazine and CCNU for Recurrent Glioblastoma
